v3.22.4
Equity - Stock Options (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
May 08, 2020
Allergan plc        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock options issued to Allergan's equity award holders (in shares) [1]       11,200
Stock Options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Contractual term 10 years      
Vesting period 3 years      
Exercise price for awards granted as percentage of market value on the date of grant 100.00%      
Weighted-average grant-date fair value of the stock options granted (in dollars per share) $ 22.83 $ 16.28 $ 12.14  
Options        
Outstanding at the beginning of the period (in shares) 12,374      
Granted (in shares) 863      
Exercised (in shares) (3,764)      
Lapsed and forfeited (in shares) (153)      
Outstanding at the end of the period (in shares) 9,320 12,374    
Exercisable at the end of the period (in shares) 7,120      
Weighted- average exercise price        
Outstanding at the beginning of the period (in dollars per share) $ 81.98      
Granted (in dollars per share) 144.54      
Exercised (in dollars per share) 70.85      
Lapsed and forfeited (in dollars per share) 107.65      
Outstanding at the end of the period (in dollars per share) 91.84 $ 81.98    
Exercisable at the end of the period (in dollars per share) $ 84.54      
Weighted-average remaining life (in years)        
Outstanding 4 years 9 months 18 days 4 years 8 months 12 days    
Exercisable 3 years 8 months 12 days      
Aggregate intrinsic value        
Outstanding $ 650 $ 661    
Exercisable 549      
Aggregate intrinsic value of options exercised 295 $ 239 $ 186  
Total fair value of options vested 21      
Unrecognized compensation cost $ 6      
Period for recognition of unrecognized compensation cost 2 years      
[1] Represents the pre-acquisition service portion of the fair value of 11 million AbbVie stock options and 8 million RSUs issued to Allergan equity award holders.